Related Experiment Videos
Local disodium cromoglycate is ineffective in ulcerative proctosigmoiditis
Acta Medica Scandinavica
|January 1, 1986
Summary
Disodium cromoglycate (DSCG) enemas did not improve ulcerative proctosigmoiditis symptoms or inflammation in a double-blind study. This study found no significant differences between DSCG and placebo for inflammatory bowel disease patients.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Conflicting evidence exists regarding the efficacy of disodium cromoglycate (DSCG) for inflammatory bowel disease.
- Previous studies have yielded varied results with oral and rectal administration of DSCG.
Purpose of the Study:
- To evaluate the efficacy of rectal disodium cromoglycate (DSCG) in treating active ulcerative proctosigmoiditis.
- To compare DSCG enemas against a placebo in patients with ulcerative proctosigmoiditis.
Main Methods:
- A double-blind, placebo-controlled study involving 43 patients with active ulcerative proctosigmoiditis.
- Patients received either 600 mg DSCG rectally as enemas or a placebo for eight weeks.
- Clinical assessments, endoscopy, laboratory tests, biopsies, and diary cards were used for evaluation.
Main Results:
- No statistically significant differences were observed between the DSCG and placebo groups in bowel frequency, rectal bleeding, or general well-being.
- Abdominal pain, disease severity, and extent showed no significant improvement with DSCG treatment.
- Histologic parameters and reported side-effects did not differ significantly between the groups.
Conclusions:
- Rectal administration of disodium cromoglycate (DSCG) did not demonstrate efficacy in improving symptoms or inflammatory changes in ulcerative proctosigmoiditis.
- DSCG enemas were found to be ineffective for this patient population.
- The study suggests that DSCG is not a beneficial treatment for active ulcerative proctosigmoiditis.